volume 15 | Issue 1
volume 15 | Issue 1
volume 15 | Issue 1
volume 15 | Issue 1
volume 15 | Issue 1
Objective: The objective of this study is to review the outcomes of gestational trophoblastic disease in our center, and to compare it with international figures. We will calculate the rates of remission, recurrence, and mortality. Also, we will determine the mean duration taken for normalization of β-hCG level after initiation of treatment, and the distribution of the disease by age and parity. Methods: Retrospective chart review of the patients diagnosed with gestational trophoblastic disease (GTD) and treated in King Khalid National Guard Hospital in the period between January 2000 and December 2005. Results: During the study period, there were 29 cases of gestational trophoblastic disease. The majority of the cases were non-metastatic GTD (55.2%) followed by, in decreasing order of frequency, molar pregnancy (24.1%), metastatic high-risk GTD (10.3%), metastatic low-risk GTD (6.9%) and placental-site trophoblastic tumor (3.4%). Patient's age ranged from sixteen to fifty-three years old, with the majority in the fourth decade of life (37.9%). The parity as well was highly variable from zero to fifteen, with the majority between five and ten (37.9%). Remission rate in the malignant GTD was 85.7%. There were no cases of recurrence during the follow-up period. The overall mortality rate was 3.4%. The mean duration required for normalization of β-hCG level was 10.3 weeks for molar pregnancy and 11.6 weeks for malignant GTD. Conclusion: The chemotherapy success rate, remission rate & mortality rate were similar to that reported in earlier studies. There is a need for patient education regarding strict follow-up for early detection and intervention of malignant sequelae.